Effectiveness, safety, initial optimal dose, and optimal maintenance dose range of basal insulin regimens for type 2 diabetes: A systematic review with meta-analysis.

Publisher: Blackwell Publishing Asia Country of Publication: Australia NLM ID: 101504326 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1753-0407 (Electronic) Linking ISSN: 17530407 NLM ISO Abbreviation: J Diabetes Subsets: MEDLINE

Original Publication: Richmond, Vic. : Blackwell Publishing Asia, 2009-

Diabetes Mellitus, Type 2*/drug therapy ; Hypoglycemia*; Humans ; Insulin Glargine/therapeutic use ; Insulin, Long-Acting/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Insulin/therapeutic use ; Insulin Detemir/therapeutic use ; Insulin, Isophane

Aims: To investigate the effectiveness, safety, optimal starting dose, optimal maintenance dose range, and target fasting plasma glucose of five basal insulins in insulin-naïve patients with type 2 diabetes mellitus.
Methods: MEDLINE, EMBASE, Web of Science, and the Cochrane Library were searched from January 2000 to February 2022. The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines were followed and the Grading of Recommendations, Assessment, Development, and Evaluations (GRADE) approach was adopted. The registration ID is CRD42022319078 in PROSPERO.
Results: Among 11 163 citations retrieved, 35 publications met the planned criteria. From meta-analyses and network meta-analyses, we found that when injecting basal insulin regimens at bedtime, the optimal choice in order of most to least effective might be glargine U-300 or degludec U-100, glargine U-100 or detemir, followed by neutral protamine hagedorn (NPH). Injecting glargine U-100 in the morning may be more effective (ie, more patients archiving glycated hemoglobin < 7.0%) and lead to fewer hypoglycemic events than injecting it at bedtime. The optimal starting dose for the initiation of any basal insulins can be 0.10-0.20 U/kg/day. There is no eligible evidence to investigate the optimal maintenance dose for basal insulins.
Conclusions: The five basal insulins are effective for the target population. Glargine U-300, degludec U-100, glargine U-100, and detemir lead to fewer hypoglycemic events than NPH without compromising glycemic control.
(© 2023 The Authors. Journal of Diabetes published by Ruijin Hospital, Shanghai Jiaotong University School of Medicine and John Wiley & Sons Australia, Ltd.)

Diabetes Obes Metab. 2020 Apr;22(4):612-621. (PMID: 31797549)
BMJ. 2021 Mar 29;372:n71. (PMID: 33782057)
J Diabetes Res. 2021 Jul 14;2021:5524313. (PMID: 34337072)
Endocrine. 2021 Dec;74(3):508-517. (PMID: 34599695)
Diabetes Obes Metab. 2019 Aug;21(8):1973-1977. (PMID: 30938035)
Cochrane Database Syst Rev. 2020 Nov 9;11:CD005613. (PMID: 33166419)
Diabetes Obes Metab. 2015 Jan;17(1):15-22. (PMID: 24957785)
BMJ. 2019 Aug 28;366:l4898. (PMID: 31462531)
Diabetes Obes Metab. 2015 Apr;17(4):386-94. (PMID: 25641260)
Diabetes Obes Metab. 2013 Aug;15(8):729-36. (PMID: 23421331)
Diabetes Res Clin Pract. 2017 Aug;130:237-243. (PMID: 28651211)
Horm Metab Res. 2016 Jan;48(1):42-7. (PMID: 26340704)
Horm Metab Res. 2003 Mar;35(3):189-96. (PMID: 12734781)
Diabetes Obes Metab. 2020 Mar;22(3):346-354. (PMID: 31646724)
Diabetes Obes Metab. 2020 May;22(5):838-846. (PMID: 31944546)
Diabetologia. 2006 Mar;49(3):442-51. (PMID: 16456680)
J Diabetes. 2023 May;15(5):419-435. (PMID: 37038616)
Diabetes Ther. 2019 Jun;10(3):835-852. (PMID: 31020539)
Diabetes Obes Metab. 2021 Jul;23(7):1588-1593. (PMID: 33687748)
Saudi J Anaesth. 2021 Oct-Dec;15(4):431-434. (PMID: 34658732)
Diabetes Obes Metab. 2010 May;12(5):437-41. (PMID: 20415692)
Diabetes Care. 2000 Aug;23(8):1130-6. (PMID: 10937510)
Health Qual Life Outcomes. 2015 Jun 09;13:77. (PMID: 26055391)
Clin Ther. 2006 Oct;28(10):1569-81. (PMID: 17157113)
BMC Endocr Disord. 2022 Jan 19;22(1):26. (PMID: 35045841)
Diabetes Obes Metab. 2020 Aug;22(8):1369-1377. (PMID: 32243043)
Diabetes Care. 2018 Oct;41(10):2147-2154. (PMID: 30104294)
Prim Care Diabetes. 2014 Oct;8(3):256-64. (PMID: 24522170)
Diabetes Res Clin Pract. 2007 Apr;76(1):111-8. (PMID: 17011662)
Diabetes Care. 2003 Nov;26(11):3080-6. (PMID: 14578243)
Ann Intern Med. 2003 Jun 17;138(12):952-9. (PMID: 12809451)
Diabetes Ther. 2021 May;12(5):1399-1413. (PMID: 33738774)
Diabetologia. 2008 Mar;51(3):408-16. (PMID: 18204830)
Diabetes Care. 2012 Dec;35(12):2464-71. (PMID: 23043166)
J Diabetes Investig. 2013 Nov 27;4(6):605-12. (PMID: 24843715)
Diabetes Metab. 2017 Sep;43(4):351-358. (PMID: 28622950)
Arch Med Res. 2006 May;37(4):495-501. (PMID: 16715577)
Diabetes Res Clin Pract. 2011 Mar;91(3):293-9. (PMID: 21146881)
J Clin Epidemiol. 2021 Sep;137:163-175. (PMID: 33857619)
Diabetes Obes Metab. 2009 Jun;11(6):623-31. (PMID: 19515182)
Drugs R D. 2016 Jun;16(2):239-49. (PMID: 27098525)
Cardiovasc Diabetol. 2014 Oct 11;13:137. (PMID: 25300286)

Sponsored by the Chinese Geriatric Endocrine Society

Keywords: 2型糖尿病; basal insulin; effectiveness; initiation and maintenance dose; safety; systematic review; type 2 diabetes; 基础胰岛素; 安全; 有效性; 系统评价; 起始和维持剂量
Local Abstract: [Publisher, Chinese] 目的:探讨5种基础胰岛素治疗在尚未接受胰岛素治疗的2型糖尿病(T2DM)患者的有效性、安全性、最佳起始剂量、最佳维持剂量范围及空腹血糖目标。 方法:检索2000年1月至2022年2月MEDLINE、EMBASE、Web of Science、Cochrane Library等数据库。遵循系统综述和meta分析的首选报告项目(PRISMA)指南并采用建议、评估、发展和评价的分级(GRADE)方法。在PROSPERO的注册ID为CRD42022319078。 结果:共检索到文献11163篇, 符合纳入标准的文献35篇。从meta分析和网络meta分析中, 我们发现, 在睡前注射基础胰岛素方案时, 最优选择可能是甘精胰岛素U-300或德谷胰岛素U-100、甘精胰岛素U-100或地特胰岛素, 其次是低精蛋白锌胰岛素(NPH)。与睡前注射相比, 早晨注射甘精胰岛素U-100可能更有效(即更多患者能够实现HbA 1c <7.0%), 且低血糖事件更少。任何基础胰岛素起始的最佳起始剂量可为0.10-0.20 U/kg/天。没有合适的证据来研究基础胰岛素的最佳维持剂量。 结论:5种基础胰岛素对目标人群有效。与NPH相比, 甘精胰岛素U-300、德谷胰岛素U-100、甘精胰岛素U-100和地特胰岛素在不影响血糖控制的情况下可减少低血糖事件。.

2ZM8CX04RZ (Insulin Glargine)
0 (Insulin, Long-Acting)
0 (Hypoglycemic Agents)
0 (Insulin)
4FT78T86XV (Insulin Detemir)
53027-39-7 (Insulin, Isophane)

Date Created: 20230411 Date Completed: 20230512 Latest Revision: 20230513

20240829

PMC10172019

10.1111/1753-0407.13381

37038616